Functional polymorphism of genes inactivating biogenic amines and cognitive deficits in paranoid schizophrenia;Funkcjonalny polimorfizm genów enzymów inaktywujacych aminy biogenne a deficyty procesów poznawczych w schizofrenii paranoidalnej

Psychiatria Polska

Volumn 47, Issue 2, 2013, Pages 197-211

  Tylec, Aneta ^a   Kucharska Pietura, Katarzyna ^b   Jeleniewicz, Witold ^c   Cybulski, Marek ^c   Czernikiewicz, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF HULL   (United Kingdom)

^c NONE   (Poland)

Author keywords

Cognitive deficits; COMT; MAO A; Schizophrenia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BIOGENIC AMINE; CATECHOL METHYLTRANSFERASE; METHIONINE; VALINE;

ALLELE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORADRENERGIC SYSTEM; PARANOID SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; VARIABLE NUMBER OF TANDEM REPEAT;

CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT;

EID: 84878000314     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Williams H, Owen M, O'Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr. Bull. 2007; 33 (3): 635-641.
2. Tylec A, Kucharska-Pietura K, Stryjecka-Zimmer M. Endofenotypy w schizofrenii. Post. Psychiatr. Neurol. 2008; 17 (3): 213-217.
3. Diaz-Asper C, Goldberg T, Kolachana B, Straub R, Egan M, Weinberger D. Genetic variation in catechol-O-methyltransferase: Effects on working memory in schizophrenic patients, their siblings, and healthy controls. Biol. Psychiatry 2008; 63 (1): 72-79.
4. Barnett J, Jones P, Robbins T, Müller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: A meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Molecular Psychiatry 2007; 12 (5): 502-509.
5. Stein D, Newman T, Savitz J, Ramesar R. Warriors versus worriers: The role of COMT gene variants. CNS Spectr. 2006; 11 (10): 745-748.
6. Nolan K, Bilder R, Lachman H, Volavka J. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am. J. Psychiatry 2004; 161 (2): 359-361.
7. Doug H, Baik S, Kyung J, Young S, Na C, Doo B, In K. Effects of catechol-O-methyltransferase Val158Met polymorphism on the cognitive stability and aggression in the first-onset schizophrenic patients. NeuroRep. 2006; 17 (1): 95-99.
8. Krabbendam L, Isusi P, Galdos P, Echevarria E, Bilbao J, Martin-Pagola A, Papiol S, van Os J. Associations between COMTVal158Met polymorphism and cognition: direct or indirect effects? Europ. Psychiatry 2006; 21 (5): 338-342.
9. Tsai S, Yu Y, Chen T, Chen J, Liou Y, Chen M, Hong C. Association study of a functional catechol-O-methyltransferase gene polymorphism and cognitive function in healthy females. Neurosc. Lett. 2003; 338: 23-126.
10. Golimbet V, Gritsenko I, Alfimova M, Lebedev I, Lezheiko T, Abramova L, Kaleda V, Ebstein R. Association study of COMT gene Val158Met polymorphism with auditory P300 and performance on neurocognitive tests in patients with schizophrenia and their relatives. World J. Biol. Psychiatry 2006; 7 (4): 238-245.
11. Bilder R, Volavka J, Czobor P, Malhotra A, Kennedy J i in. Neurocognitive correlates of the COMTVal (158)Met polymorphism in chronic schizophrenia. Biol. Psychiatry 2002; 52: 701-707.
12. Goldberg T, Egan M, Gscheidle T, Coppola R, Weickert T i in. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch. Gen. Psychiatry 2003; 60 (9): 889-896.
13. Stefanis N, Van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I i in. Variation in catechol-omethyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry 2004; 56: 510-515.
14. Tylec A, Stryjecka-Zimmer M, Kucharska-Pietura K. Genetic polymorphism of a MAO in mental disorders. Psychiatr. Pol. 2007; 41 (4): 485-493.
15. Kerage F, Bovier J, Tissot R. The decrease of erythrocyte catechol-O-methyltransferase activity in depressed patients and its diagnostic significance. Acta Psychiatr. Scand. 1987; 76: 303-308.
16. Strous R, Bark N, Woerner M, Lachman H. Lack of association of a functional catechol-Omethyltransferase gene polymorphism in schizophrenia. Brief Rep. Biol. Psychiatry 1997; 41: 493-495.
17. Volavka J. Neurobiology of violence. Washington, DC: American Psychiatric Press; 1995.
18. Corcoran R, Mercer G, Frith C. Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Schizophr. Res. 1995; 17 (1): 5-13.
19. Robertson I, Ward T, Ridgeway V, Nimmo-Smith I. The structure of normal human attention: The Test of Everyday Attention. J. Int. Neuropsychol. Soc. 1996; 2 (6): 525-534.
20. Whittaker J. Face processing in schizophrenia: defining the deficit. Psychol. Med. 2001; 31: 499-507.
21. Warrington E, James M. A new test of object decision: 2D silhouettes featuring a minimal view. Cortex 1991; 27 (3): 370-383.
22. Norton N, Kirov G, Zammit S, Jones G, Jones S i in. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: No evidence for association or epistasis. Am. J. Med. Gen. Neuropsychiatr. Gen. 2002; 114 (5): 491-496.
23. Altman DG, Gore SM. Statistics in practice. London: British Medical Association; 1982.
24. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006; 5: 311-328.
25. Krach S, Jansen A, Krug A, Markov V, Thimm M i in. COMT genotype and its role on hippocampal- prefrontal regions in declarative memory. Neuroim. 2010; 53: 978-984.
26. Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, Bernstein H i in. The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J. Neurosc. 2006; 26: 1407-1417.
27. Dennis NA, Need AC, LaBar KS, Waters-Metenier S, Cirulli ET, Kragel J i in. COMT val108/158 met genotype affects neural but not cognitive processing in healthy individuals. Cerebr. Cortex 2010; 20: 672-683.
28. Greenwood K, Hung CF, Tropeano M, McGuffin P, Wykes T. No association between the catechol-O-methyltransferase (COMT) val158met polymorphism and cognitive improvementfollowing cognitive remediation therapy (CRT) in schizophrenia. Neurosc. Lett. 2011; 496 (2): 65-69. doi: 10.1016/j.neulet.2011. 03.075.
29. Rybakowski J, Borkowska A, Czerski P, Dmitrzak-Weglarz M, Skibińska M, Kapelski P, Hauser J. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry Res. 2006; 30, 143 (1): 13-19.
30. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martínez- Larrea A, Fañanás L. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am. J. Psychiatry 2004; 161 (6): 1110-1112.
31. Solís-Ortiz S, Pérez-Luque E, Morado-Crespo L, Gutiérrez-Muñoz M. Executive functions and selective attention are favored in middle-aged healthy women carriers of the Val/Val genotype of the catechol-O-methyltransferase gene: a behavioral genetic study. Behav. Brain Funct. 2010; 29 (6): 67.
32. Ehlis A, Reif A, Herrmann M, Lesch K, Fallgatter A. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacol. 2007; 32 (1): 162-170.
33. MacDonald III A, Carter C, Flory J, Ferrell R, Manuck S. COMT Val158Met and executive control: A test of the benefit of specific deficits to translational research. J. Abnorm. Psychol. 2007; 116 (2): 306-312.
34. Jeffrey S, Bedwell W, Kamath V, Baksh E. Comparison of three computer-administered cognitive tasks as putative endophenotypes of schizophrenia. Schizophr. Res. 2006; 88: 36-35.
35. Szöke A, Schürhoff F, Méary A, Mathieu F, Chevalier F, Trandafir A, Alter C, Roy I, Bellivier F, Leboyer M. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006; 141B (5): 504-512.
36. Bray N, Buckland P, Williams N, Williams H, Norton N, Owen M, O'Donovan M. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 2003; 73: 152-161.
37. Pelayo-Teran J, Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, Mata I i in. Catechol- O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode nonaffective psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008; 147B (5): 550-556.
38. Van Winkel R, Isusi P, Galdos P, Echevarria E, Bilbao J i in. Evidence that the COMT Val158Met polymorphism moderates subclinical psychotic and affective symptoms in unaffected first-degree relatives of patients with schizophrenia. Eur. Psychiatry 2008; 23 (3): 219-222.
39. Herken H, Erdal M. Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr. Genet. 2001; 11 (2): 105-109.
40. Molero P, Ortuño F, Zalacain M, Patiño-García A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogen. J. 2007; 7 (6): 418-426.
41. Strous R, Lapidus R, Viglin D, Kotler M, Lachman H. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosc. Lett. 2006; 393 (2-3): 170-173.
42. Tybura P, Grzywacz A, Syrek S, Parus M, Samochowiec J. Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment. Psychiatr. Pol. 2006; 40 (5): 913-923.
43. Tsai S, Hong C, Liao D, Lai I, Liou Y. Association study of a functional catechol-O-methyltransferase genetic polymorphism with age of onset, cognitive function, symptomatology and prognosis in chronic schizophrenia. Neuropsychobiol. 2004; 49 (4): 196-200.
44. Egan M, Goldberg T, Kolachana B, Callicott J, Mazzanti C i in. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceed. Nat. Acad. Sc. 2001: 98 (12): 6917-6922.
45. Poletti S, Radaelli D, Cavallaro R, Bosia M, Lorenzi C i in. Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. Compr. Psychiatry 2013; 54 (2): 181-186.
46. Tan H, Chen A, Kolachana B, Apud J, Mattay V i in. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. Brain 2012; 135 (5): 1436-1445.
47. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J i in. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004; 9 (5): 442-473.